Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

690 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
ERAPSO: Revealing the High Burden of Obesity in German Psoriasis Patients.
Schwarz PEH, Pinter A, Melzer N, Barteczek P, Reinhardt M. Schwarz PEH, et al. Among authors: pinter a. Dermatol Ther (Heidelb). 2019 Sep;9(3):579-587. doi: 10.1007/s13555-019-0314-1. Epub 2019 Jul 11. Dermatol Ther (Heidelb). 2019. PMID: 31297711 Free PMC article.
Patient-reported outcomes with risankizumab versus fumaric acid esters in systemic therapy-naïve patients with moderate to severe plaque psoriasis: a phase 3 clinical trial.
Thaçi D, Soliman AM, Eyerich K, Pinter A, Sebastian M, Unnebrink K, Rubant S, Williams DA, Weisenseel P. Thaçi D, et al. Among authors: pinter a. J Eur Acad Dermatol Venereol. 2021 Aug;35(8):1686-1691. doi: 10.1111/jdv.17109. Epub 2021 Jul 12. J Eur Acad Dermatol Venereol. 2021. PMID: 33428281 Clinical Trial.
Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study.
Crowley JJ, Langley RG, Gordon KB, Pinter A, Ferris LK, Rubant S, Photowala H, Xue Z, Wu T, Zhan T, Beeck S, Shah M, Warren RB. Crowley JJ, et al. Among authors: pinter a. Dermatol Ther (Heidelb). 2022 Feb;12(2):561-575. doi: 10.1007/s13555-021-00679-6. Epub 2022 Jan 20. Dermatol Ther (Heidelb). 2022. PMID: 35050485 Free PMC article.
Long-term, durable, absolute Psoriasis Area and Severity Index and health-related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate-to-severe plaque psoriasis.
Gooderham M, Pinter A, Ferris LK, Warren RB, Zhan T, Zeng J, Soliman AM, Kaufmann C, Kaplan B, Photowala H, Strober B. Gooderham M, et al. Among authors: pinter a. J Eur Acad Dermatol Venereol. 2022 Jun;36(6):855-865. doi: 10.1111/jdv.18010. Epub 2022 Mar 17. J Eur Acad Dermatol Venereol. 2022. PMID: 35174556 Free PMC article. Clinical Trial.
Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse).
Stein Gold LF, Bagel J, Tyring SK, Hong HC, Pavlovsky L, Vender R, Pinter A, Reich A, Drogaris L, Wu T, Patel M, Soliman AM, Photowala H, Stakias V, Richter S, Papp KA. Stein Gold LF, et al. Among authors: pinter a. Br J Dermatol. 2023 Oct 25;189(5):540-552. doi: 10.1093/bjd/ljad252. Br J Dermatol. 2023. PMID: 37488811 Clinical Trial.
Comparative Effectiveness and Durability of Biologics in Clinical Practice: Month 12 Outcomes from the International, Observational Psoriasis Study of Health Outcomes (PSoHO).
Pinter A, Costanzo A, Khattri S, Smith SD, Carrascosa JM, Tada Y, Riedl E, Reich A, Brnabic A, Haustrup N, Lampropoulou A, Lipkovich I, Kadziola Z, Paul C, Schuster C. Pinter A, et al. Dermatol Ther (Heidelb). 2024 Jun;14(6):1479-1493. doi: 10.1007/s13555-023-01086-9. Epub 2023 Dec 19. Dermatol Ther (Heidelb). 2024. PMID: 38113010 Free PMC article.
690 results